GlobeNewswire Inc | Jan 15, 2021 01:30PM EST

January 15, 2021

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB:EMBI) (EMBI orthe Company), a biopharmaceutical company focused on developingproprietary, syntheticcannabinoid-derived moleculesto treat glaucoma and other diseases with significant unmet need,has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. The Companywill trade under itsnew ticker symbol, SKYE,on the OTCeffective atmarket open on Tuesday, January 19, 2021.

AboutEmeraldBioscience, Inc.

EmeraldBioscienceInc.is a biopharmaceutical company developingdifferentiated,proprietary cannabinoid-derived moleculesto treatdiseases with significant unmet needs.The Companys leadmolecule, in preclinical studies, hasdemonstrated potentialasa new classoftherapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to currently available drugs.For more information,pleasevisit www.emeraldbio.life.

CONTACTKaram TakharVP,Corporate Development & Investor RelationsEmail: ir@emeraldbio.life Phone: +1-949-336-3437

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy,relocation of corporate headquarters, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on managements current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including anticipated, contemplates, goal, focus, aims, intends, believes, can, could, challenge, predictable, will, would, may or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.